Headquartered in Brisbane, CA Fiscal year ends December NASDAQ: VERA veratx.com
Vera Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapies for autoimmune diseases, starting with kidney diseases. Its flagship product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor that received FDA accelerated approval for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. TRUTAKNA is a once-weekly, self-administered autoinjector and is the first and only approved therapy targeting both BAFF and APRIL. The company addresses a significant unmet need in IgAN, a serious progressive immune-mediated kidney disease affecting approximately 160,000 diagnosed patients in the U.S., with at least 50% of patients potentially progressing to kidney failure or death within 10 to 20 years of diagnosis. Vera is also evaluating additional autoimmune diseases where BAFF and APRIL inhibition may prove clinically meaningful. Founded in 2016, the company trades on Nasdaq under the ticker VERA. Updated
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Vera Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapies for autoimmune diseases, starting with kidney diseases.
The Wall Street consensus 12-month price target for VERA is $74.20.
